초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 09월 10일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

제124회 대한화학회 학술발표회, 총회 및 기기전시회 안내 YPN005, an oral CDK7 inhibitor, exhibits a significant antitumor activity in Myc-driven cancers.

2019년 8월 29일 10시 33분 27초
MEDI.P-277 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
10월 17일 (목요일) 11:00~12:30
Medicinal Chemistry
저자 및
Mijung Lee*, Jieun Min1
Department of Chemistry, Yungjin Pharm. Co., Ltd., Korea
1Medicinal Chemistry, Yungjin Pharm. Co., Ltd., Korea
CDK7 is an important regulator of both cell cycle progression and gene expression by phosphorylating cell cycle kinase (CDK1, CDK2, CDK4 and CDK6) and RNA polymerase II (RNAPII). Recent studies indicate that the inhibition of CDK7 is an attractive strategy for the treatment of cancer by down-regulation of c-Myc expression. Myc regulates the anti-tumor immune response through CD47 and PD-L1 and drives an immunosuppressive phenotype in cancer. There are no existing therapies targeting Myc, which is highly prevalent in many difficult to treat cancers. We have investigated the therapeutic efficacy of YPN005, a novel oral CDK7 inhibitor, in triple negative breast cancer (TNBC) and hepatocellular carcinoma (HCC). The therapeutic efficacy of YPN005 was evaluated in TNBC xenograft mouse model. YPN005 was orally administered at a dose of 10mpk once a day for 3 weeks. THZ-1 which is reference compound was intravenously administered at a dose of 10mpk twice a day following the same schedule. We have observed tumor volume regression without any signs of toxicity during treatment periods.